Home > Reports > Hereditary Testing Market Growth, Report to 2030

Hereditary Testing Market

Hereditary Testing Market: Information by Disease Type (Hereditary Cancer Testing, Hereditary Non-cancer Testing), and Region — Forecast till 2030

Published At : 18 Aug, 2022
Updated At : 19 Aug, 2022
Table of Content Download Sample

Market Snapshot
Base Year:
2021
Study Period:
2020-2030
CAGR:
9.12 %
Fastest Growing Market:
Asia Pacific
Largest Market:
Europe

The global hereditary testing market was valued at USD 6.12 billion in 2021. It is projected to reach USD 13.42 billion by 2030, growing at a CAGR of 9.12% during the forecast period (2022–2030). The evaluation of human genetics, lifestyle, cancer, and cardiovascular conditions is done using genetic tests, which are widely available medical procedures that come in kits and panels. The patient's blood is drawn for the test and then processed through laboratory equipment for analysis. The progression can be ascribed to the emergence of genetic testing services and the rising desire for personalized therapy.

The introduction of cutting-edge technologies in genetic testing has decreased the sequencing time and costs associated with genetic testing. The key factors driving market expansion are increasing the frequency of inherited problems, heightened public awareness of the harmful implications, advances in genetic analysis, and the emergence of rare diseases.

Get more information on this report Download Sample Report

Market Dynamics

Global Hereditary Testing Market Drivers

Growth in the Field of Reproductive Genetics and Health

One of the essential factors driving this market is the rapidly growing field of reproductive genetic health. Key participants in women's health genetic testing for inherited disorders, such as Natera, have reported an ongoing growth in the total number of tests performed. This reflects the increased acceptance of genetic testing among the general community, accelerating revenue growth. The growing prevalence of newborn screening programs worldwide contributes to sales expansion. Revisions to the genetic testing criteria made it possible to use multigene panel testing for hereditary cancer in clinical practice. The National Comprehensive Cancer Network published the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast, ovarian, and colorectal cancers. These guidelines provide information on cancer risk factors and management.

Rising Sales of DNA Test Kits

A growth in DNA screening kit purchases is a consequence of the market's increasing demand for genetic testing. For instance, the Virginia Department of General Services Division of Integrated Laboratory Facilities tested 7,867 infants for more than 31 genetic and metabolic disorders. Changes to genetic testing techniques have led to the clinical application of multigene panel screening for inherited disorders. For ovarian, breast, and colorectal cancers, the NCCN Clinical Practice Recommendations in Oncology provide details on various cancer risk factors and treatment suggestions for single and multiple panels. The market for inherited genetic testing is anticipated to benefit from gradual modifications to the distribution strategy. Technological providers play a crucial part in the market by bolstering distribution services and enhancing technical efficacy.

Global Hereditary Testing Market Restraints

Growth Hampered by Pandemic

The pandemic harmed the industry of inherited genetic analysis due to genetic counselors' inability to see clients in person, doctors' difficulty in providing advice, and the laboratory's inability to perform the tests. Furthermore, because regulatory agencies such as the Centers for Medicare and Medicaid Services (CMS) did not recognize genetic counselors as healthcare professionals, they were barred from working during government shutdowns. Additionally, clinics curtailed face-to-face diagnostic tests to minimize the transmission of the disease. Nonetheless, genetic testing behemoths such as GeneDx offered genetic screening as a service upon clinician request.

Global Hereditary Testing Market Opportunities

New Medical Tests and Improved Health Results

The national comprehensive cancer network provides information on several cancer risk factors and therapy recommendations for single and multiple genetic panels. By enhancing distribution services and increasing technical efficacy, technological service providers contribute to the market expansion. Corporations use a cloud-based distribution approach to make bioinformatics technologies accessible to other universities. Approximately fourteen licensees have started aggressively marketing non-invasive prenatal testing devices using constellation software. Even though these genetic tests have substantial advantages over conventional testing, several industry professionals cited the test's expense and security risks. Furthermore, the lack of adequate testing regulation is a critical issue that requires immediate attention. Despite these challenges, the genetic testing market is growing due to the advantages of these ground-breaking tests and improved healthcare outcomes.

Segmental Analysis

The global hereditary testing market is segmented by disease type.

On the Basis of Disease Type

Based on disease type, the market is segmented into hereditary cancer testing and hereditary non-cancer testing.

The hereditary non-cancer testing segment dominates the global market and is anticipated to grow at a substantial CAGR during the forecast period. Large competitors entering this market, like Quest, have significantly impacted recent market growth. Businesses are attempting to strengthen their position in this market because they perceive breast cancer genetic testing as a sizable revenue source. Offering genetic tests at a lower cost than rivals is one of the strategies. For instance, Color Genomics started charging USD 259 for its product, whereas Myriad charged over USD 4,000 for identical items. The increasing affordability of the tests is one of the primary factors driving this market segment. In addition, BRCA1 carriers have an 80% chance of developing breast cancer, which has expedited the growth of the market for hereditary cancer testing.

Among the common cancer types with few effective treatments is lung cancer, which has no connection to inherited genetic abnormalities. Similarly, most occurrences of cervical cancer are caused by Human Papilloma Virus (HPV) rather than genetic changes. The lack of sufficient evidence regarding the hereditary nature of cervical cancer drives this market.

Regional Analysis

The global hereditary testing market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

Hereditary Testing Market Regional Analysis

Regional Growth Insights Request Sample Pages

Europe is the most significant revenue shareholder and is anticipated to maintain its lead during the forecast period. This can be ascribed to significant actors conducting genetic tests, the widespread acceptance of modern treatments, and recommendations offered by government bodies to ensure the quality of services supplied by hereditary testing companies. The approval and marketing of hereditary tests market have been profoundly impacted by the variations in regulatory frameworks of hereditary testing in different parts of the world.

Many essential companies in the United States of America and several nations in Europe, Asia Pacific, and other regions are currently offering various hereditary tests. Quest and Blueprint Genetics will facilitate improvements in patient care and advances in pharmaceutical research and development by improving access to actionable insights into genetic and uncommon illnesses. These activities are anticipated to improve the genetic testing landscape for hereditary illnesses in North America, ultimately accelerating revenue generation in the region.

Competitive Players

The global hereditary testing market’s major key players are

  • Myriad Genetics, Inc.
  • Invitae Corporation
  • Illumina, Inc.
  • Natera, Inc.
  • Laboratory Corporation of America Holdings
  • Hoffmann-La Roche Ltd
  • Quest Diagnostics Incorporated
  • CooperSurgical, Inc.
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific, Inc.

Recent Developments

  • June 2022- Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration.
  • May 2022- Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022.
  • May 2022- Invitae Corporation, New Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access.
  • June 2022- Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome.

Global Hereditary Testing Market: Segmentation

By Disease Type

  • Hereditary Cancer Testing
  • Hereditary Non-cancer Testing

By Regions

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
Free Sample Report